Antonio Martin Jimenez Jimenez, MD

Articles by Antonio Martin Jimenez Jimenez, MD

Dr Jimenez Jimenez on the Clinical Implications of the ACCESS Trial in Hematological Malignancies

August 1st 2024

Antonio Martin Jimenez Jimenez, MD, discusses the clinical implications of PBSC from HLA-MMUD and PTCy for GVHD prophylaxis in hematological malignancies.

Dr Jimenez Jimenez on PBSC from HLA-Mismatched Donors in Hematological Malignancies

ByAntonio Martin Jimenez Jimenez, MD

June 21st 2024

Antonio Martin Jimenez Jimenez, MD, discusses conditioning therapy, PBSC from HLA-MMUD, and PTCy for GVHD prophylaxis in hematological malignancies.

Antonio Martin Jimenez Jimenez, MD

Articles by Antonio Martin Jimenez Jimenez, MD

Dr Jimenez Jimenez on the Clinical Implications of the ACCESS Trial in Hematological Malignancies

Dr Jimenez Jimenez on PBSC from HLA-Mismatched Donors in Hematological Malignancies

Latest Updated Articles

Trending on OncLive

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg

Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL

Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis

ESAONA Data Support Asandeutertinib as a Frontline Option in EGFR+ NSCLC With Brain Metastases